Bioprocess consumables pure-play: ATF perfusion systems, chromatography resins, filtration. The Manufacture-layer analog to WST/STVN. Qualification moat — once a process is locked, demand is welded.
Research snapshot · Not reviewed
RGENRepligen
Upstream bioprocessing, ATF systems, perfusion
Open RGEN in Robinhood ↗Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$8.03BSnapshot value
Bioprocess cycle recovery (consumables growing ~10% YoY post-18mo destocking); process intensification (N-1 perfusion, continuous processing) driving equipment + consumable demand; ADC bioconjugation tailwind.
Cyclicality/destocking redux (same stickiness that locks demand caused 2023-24 revenue drop); equipment lag (instruments trailing consumables recovery); customer in-housing risk; premium valuation.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟢 Lean-Bull · ins-$0.6M · 13F 21+/4- · short↑0.3
Snapshot · Not reviewed